News Category
TransCode Therapeutics has initiated a formal strategic review to evaluate options for maximizing value, including potential licensing, partnerships, ...
Enodia Therapeutics has appointed Henrik Torp Nielsen as Chief Financial Officer to lead financial strategy as the company advances its proprietary Se...
Certified-PEP's 2026 comparison of 10 research peptide suppliers highlights the importance of batch-specific Certificates of Analysis and transparent ...
Creative Biolabs' tumor organoid co-culture models offer a more physiologically relevant 3D platform for evaluating CAR-T cell activity, addressing a ...
Creative Biolabs has introduced an integrated OMV and exosome-boosted CAR-T development platform to help researchers address poor infiltration, immuno...
GeoVax Labs has entered a $1 million revolving loan agreement with Bowery Consulting Group, leading to a major board restructuring that could impact t...
TransCode Therapeutics reported positive Phase 1a safety results for TTX-MC138 at ESMO Congress 2026, with no dose-limiting toxicities and early signs...
Oncotelic Therapeutics published a peer-reviewed study showing its PDAOAI platform identified a four-gene prognostic signature in liver cancer, a step...
Tonix Pharmaceuticals will report third-quarter 2026 financial results on Nov. 9, a disclosure that gives investors a timely look at the commercial ro...
Coherence Neuro's $45 million Series A, backed by Peter Thiel and OpenAI, will fund a first chronic human trial of its SOMA implant for glioblastoma, ...
Adaptogenics Health Corp. is advancing a dual commercial and therapeutic strategy in the peptide sector, combining supply infrastructure, proprietary ...
VERAXA Biotech is implementing New Approach Methodologies across its preclinical oncology programs, aiming to improve clinical translation and reduce ...
VERAXA Biotech is advancing its BiTAC platform to create antibody-based cancer therapies that activate only when two targets are present on the same t...
SS Innovations International (NASDAQ: SSII) has launched Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo using its SSi Man...
Regentis Biomaterials has achieved a 400% increase in manufacturing yield for its GelrinC cartilage implant following European regulatory approval, wh...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article that highlighted promising but li...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies across its preclinical programs, aiming to generate more human-relevant data and...
A new study reveals that ISAba1-mediated amplification of the crp-osmC gene cluster enhances Acinetobacter baumannii host adaptation but reduces biofi...
A UK study finding that clearing immune fog can stop lung cancer before diagnosis underscores the promise of cancer interception, a field gaining prom...
Scinai Immunotherapeutics' CDMO subsidiary secured a $5.1 million development and clinical manufacturing agreement with a U.S. Nasdaq-listed biopharma...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to execute a Phase 2 trial of Lucid-MS, a nove...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies across its preclinical programs, potentially accelerating clinical advancement, ...
Lantern Pharma's Taiwan regulatory and IRB approvals for the Phase 2 HARMONIC trial of LP-300 enable expansion of a biomarker-driven study targeting E...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business to launch a Phase 2 trial of Lucid-MS signals a potential paradigm shift...
VERAXA Biotech (NASDAQ: VRXA) is implementing FDA-aligned New Approach Methodologies to reduce animal testing, accelerate clinical advancement, and cu...
XORTX Therapeutics is positioning its proprietary gout treatment XORLO for a New Drug Application submission to the FDA within a year, aiming to addre...
Quantum BioPharma has entered a Study Start-Up Agreement with Thermo Fisher Scientific to initiate its Phase 2 trial of Lucid-MS for multiple sclerosi...
Telomir Pharmaceuticals raised approximately $5.6 million in a PIPE financing that will fund clinical development of Telomir-Zn, including a Phase 1/2...
NanoViricides' upcoming presentation at the NIBA 153rd Investment Conference highlights its progress on NV-387, a broad-spectrum antiviral in Phase 2 ...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher's clinical research business marks a critical step toward launching a Phase 2 trial fo...
A new study reveals lymph-node-like structures in the skull's bone marrow that may serve as a local immune defense for the brain, potentially opening ...
Kairos Pharma's Phase 2 trial of ENV-105 in metastatic castration-resistant prostate cancer demonstrates a median PFS of 17.7 months versus 2 months f...
AXIM Biotechnologies' 510(k) submission for a next-generation tear lactoferrin test could bring objective, 10-minute dry eye diagnosis directly into e...
GeoVax's upcoming presentation at World Vaccine Congress Europe 2026 will detail its next-generation MVA-X vaccine and continuous cell-line manufactur...
NHS England's new intraoperative brain tumor test, developed at the University of Nottingham, reduces genetic diagnosis time from eight weeks to two h...
NanoViricides has initiated a Phase II clinical trial of its oral NV-387 gummies for Ebola, a potential breakthrough for outbreak response in resource...
A new blood-based method for identifying cancer-specific proteins could make personalized immunotherapy faster and more accessible for patients who ca...
Silo Pharma's QwikAgents expands its AI agent platform with NVIDIA bring-your-own-key support and Hermes runtime, giving customers more flexibility an...
Quantum BioPharma's Lucid-MS is entering a Phase 2 trial in multiple sclerosis patients, marking a significant milestone for the company and potential...
Helix BioPharma Corp. has appointed four new directors and reconstituted its board and audit committee, signaling a governance renewal aimed at advanc...
Viromed Medical AG reported progress in product development and market launch in H1 2026, including regulatory approval for ViroCAP med and a new sale...
Scientists in South Korea have discovered a key protein that regulates brain cancer growth, potentially leading to new treatments for glioblastoma, th...
NanoViricides has started enrolling and dosing patients in a Phase II clinical trial of its oral antiviral NV-387 for Bundibugyo Ebolavirus in the Dem...
TransCode Therapeutics' updated Phase 1a data for TTX-MC138 demonstrate a 71.4% stable disease rate and a favorable safety profile, offering a potenti...
In vitro ADME studies are critical for early assessment of drug candidates, helping to avoid costly late-stage failures and streamline development.
GeoVax's next-generation MVA-X vaccine demonstrated durable single-dose protection against lethal Clade I mpox in preclinical models, potentially simp...
Onco-Innovations is advancing its preclinical cancer candidate ONC010 toward first-in-human testing by integrating manufacturing, nanoparticle formula...
VERAXA Biotech has named Raju Willener as CFO, bringing over 30 years of capital markets experience to support the advancement of its BiTAC oncology p...
